High Levels of Dissatisfaction Reported in Hidradenitis Suppurativa Care

Recent research indicates significant dissatisfaction among patients receiving treatment for hidradenitis suppurativa (HS), a chronic inflammatory skin condition. A study published in the Journal of Drugs in Dermatology highlights the challenges faced by individuals seeking effective management options for their condition.

Conducted by researchers at the George Washington School of Medicine and Health Sciences, the survey assessed the perceptions of current and upcoming HS treatments among participants aged 18 and older. A total of 423 individuals completed the survey, revealing troubling trends in treatment satisfaction.

Findings indicated that only 18% of respondents expressed satisfaction with their current treatment options. Notably, among participants with moderate to severe disease, as identified by Hurley stages II and III, a mere 39% were receiving biologic therapies, and only 26% were treated with hormone therapies. This underscores a significant gap in treatment adherence to established medical guidelines.

The survey also uncovered a lack of awareness regarding FDA-approved treatments among patients. Approximately 74% of participants reported they were unaware of available therapeutic options, and over half (56%) noted that their dermatologists had not discussed these treatments with them. Many respondents, 60%, emphasized the importance of having access to FDA-approved therapies, believing that such options would enhance their physical health, mental well-being, and personal relationships.

Dr. Adam Friedman, a co-author of the study, emphasized the critical need for pharmaceutical investment in the development of new treatments for HS. He pointed out the multifaceted benefits that new FDA-approved medications could provide to patients, while also highlighting the persistent gaps in care and treatment dissatisfaction that currently exist.

The study's implications suggest that healthcare providers must improve communication regarding available treatments and ensure that patients are informed of their options. Addressing these issues may lead to improved patient outcomes and overall satisfaction with the management of hidradenitis suppurativa.